Matt Hollingsworth is the Chief Innovation Officer and Co-Founder of Carta Healthcare. He said there will be a growing need for technology in 2024.
We asked our readers and some members of our editorial advisory board to make predictions for 2024. Here's what Matt Hollingsworth said:
“Although the adoption of AI in healthcare is nothing new, there will continue to be a growing need for AI technology in 2024 and beyond. With an overall lack of manpower in healthcare, as seen in nursing and staff shortage trends, AI looks like the best solution for retaining existing manpower at competitive compensation rates while increasing efficiency in workflow and improving clinician job satisfaction. According to the National Library of Medicine, the key to successful AI implementation is to do it in a clinically relevant way that clinical caregivers can get behind. It's not only about the technology, it's about how technology and caregivers work together in a trusted way to believe in, train, and commit their AI solutions to provide long-term value.”
There is no one-size-fits-all AI solution for streamlining healthcare data, as each health institution has their own unique approach and associated needs. In 2024, health leaders should avoid generalized “AI platforms” with nebulous value and instead, take a more nuanced approach. Given the excessive hype around AI at the moment, health leaders should cut through the hype by selecting solutions that provide value-based/risk-bearing engagements as opposed to SaaS contracts; that will prevent health providers from bearing the risk of the technical execution. At this point, AI has reached a degree of maturity that should no longer require providers to take a bet on a technology with a multi-million dollar SaaS contract. Technology companies should put their money where their marketing is. A successful, tailored solution requires consultation with experts familiar with the intricacies of healthcare data to employ techniques such as brute force mapping to create a stable system, while adjusting the approach periodically to keep up with changes in technology and management.”
AstraZeneca, Daiichi Sankyo Submit New BLA for Datopotamab in Lung Cancer
November 12th 2024After feedback from the FDA, the companies have voluntarily withdrawn the previous biologics licensing application for datopotamab deruxtecan for patients with advanced or metastatic nonsquamous non-small cell lung cancer.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Breast Cancer Patients Desire Early, Frequent Financial Screening
November 11th 2024Current financial screening procedures in the United States may need to change, according to recent research done by Laila Gharzai, M.D., LLM, from the Department of Radiation Oncology at Northwestern University.
Read More
In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.
Listen
The Takeaway From Study of Midlife MS Patients: Don't Stop Disease-Modifying Therapy
Published: November 11th 2024 | Updated: November 11th 2024People with multiple sclerosis (MS) often stop taking disease-modifying therapy as they transition from relapsing-remitting MS to secondary progressive MS. This study shows that people who stop stop disease-modifying therapy have higher hospitalization rates and more visits to the emergency room.
Read More